

Appendix D

Prescription Medicines for Heart Disease

The medicines commonly used for the treatment of cardiovascular disease are listed here, including those integral to the Before It Happens Plan (statins, beta-blockers and ACE inhibitors), those that may be necessary to add (diuretics, ARBs) and those that should be used only for specific situations (calcium channel blockers).

Generic Name	Brand Name
<i>Statins</i>	
atorvastatin	Lipitor
fluvastatin	Lescol, Lescol XL
lovastatin	Mevacor, Altacor
pravastatin	Pravachol
rosuvastatin	Crestor
simvastatin	Zocor
<i>Beta-Blockers</i>	
acebutolol	Sectral
atenolol	Tenormin
betaxolol	Kerlone
bisoprolol	Zebeta

APPENDIX D: PRESCRIPTION MEDICINES FOR HEART DISEASE 235

Generic Name	Brand Name
carteolol	Cartrol
carvedilol	Coreg
labetolol	Normodyne, Trandate
metoprolol succinate	Toprol-XL
metoprolol tartrate	Lopressor
nadolol	Corgard
pindolol	Visken
propranolol	Inderal
timolol	Blocadren

ACE Inhibitors

benazepril	Lotensin
captopril	Capoten
enalapril	Vasotec
fosinopril	Monopril
lisinopril	Prinivil, Zestril
moexipril	Univasc
perindopril	Aceon
quinapril	Accupril
ramipril	Altace
trandolapril	Mavik

Angiotensin Receptor Antagonists

candesartan	Atacand
eprosartan	Teveten
irbesartan	Avapro
losartan	Cozaar
olmesartan	Benicar
telmisartan	Micardis
valsartan	Diovan

236 APPENDIX D: PRESCRIPTION MEDICINES FOR HEART DISEASE

Generic Name	Brand Name
<i>Diuretics</i>	
amiloride	Midamar
amiloride + hydrochlorothiazide	Moduretic
chlorthalidone	Hygroton
furosemide	Lasix
hydrochlorothiazide	Esidrix, Hydrodiuril, Microzide
indapamide	Lozol
metolazone	Mykrox, Zaroxolyn
spironolactone	Aldactone
spironolactone + hydrochlorothiazide	Aldactazide
triamterene	Dyrenium
triamterene + hydrochlorothiazide	Dyazide, Maxzide
<i>Calcium Channel Blockers</i>	
amlodipine	Norvasc
bepidil	Vascor
diltiazem	Cardizem CD, Cardizem SR, Dilacor XR, Tiazac
felodipine	Plendil
isradipine	DynaCirc, DynaCirc CR
nicardipine	Cardene SR
nifedipine	Adalat CC, Procardia XL
nimodipine	Nimotop
nisoldipine	Sular
verapamil	Calan SR, Covera HS, Isoptin SR, Verelan

Selected Bibliography

Statistics on Cardiovascular Disease

American Heart Association. (2003) *Epidemiology of CV Disease, Heart Disease and Stroke Statistics—2003 Update*. Vol. 2003. American Heart Association.

Medicines

Beta-Blockers

- Beta Blocker Heart Attack Trial Research Group. (1982). A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. *Journal of the American Medical Association*, 247, 1707–1714. [Source for Figure 4.3]
- Bristow, M. R., Gilbert, E. M., Abraham, W. T., et al. (1996). Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. *Circulation*, 94, 2807–2816. [Source for Figure 4.3]
- CIBIS-II investigators and Committee (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet*, 353, 9–13.
- Dargie, H. J. (2001). Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. *Lancet*, 357, 1385–1390.
- Gottlieb, S. S., McCarter, R. J., & Vogel, R. A. (1998). Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *New England Journal of Medicine*, 339, 489–497.
- Hjalmarson, A., Elmfeldt, D., Herlitz, J., et al. (1981). Effect on mortality of metoprolol in acute myocardial infarction: A double-blind randomised trial. *Lancet*, 2, 823–827.
- MERIT-HF Study Group. (1999). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*, 353, 2001–2007. [Source for Figure 4.3]
- Norwegian Multicenter Study Group. (1981). Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. *New England Journal of Medicine*, 304, 801–807.

- Olsson, G., Tuomilehto, J., Berglund, G., et al. (1991). Primary prevention of sudden cardiovascular death in hypertensive patients: Mortality results from the MAPHY Study. *American Journal of Hypertension*, 4, 151–158. [Source for Figure 4.3]
- Packer, M., Coats, A. J., Fowler, M. B., et al. (2001). Effect of carvedilol on survival in severe chronic heart failure. *New England Journal of Medicine*, 344, 1651–1658. [Source for Figure 4.3]
- Packer, M., Colucci, W. S., Sackner-Bernstein, J. D., et al., for the PRECISE study group. (1996). Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. *Circulation*, 94, 2793–2799. [Source for Figure 4.3]
- Poole-Wilson, P. A., Swedberg, K., Cleland, J. G., et al. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. *Lancet*, 362, 7–13.
- Sackner Bernstein, J. D., & Mancini, D. M. (1995). Rationale for treatment of patients with chronic heart failure with adrenergic blockade. *Journal of the American Medical Association*, 274, 1462–1467.
- Wikstrand, J., Warnold, I., Olsson, G., Tuomilehto, J., Elmfeldt, D., & Berglund, G. (1988). Primary prevention with metoprolol in patients with hypertension: Mortality results from the MAPHY study. *Journal of the American Medical Association*, 259, 1976–1982.
- Yancy, C. W., Fowler, M. B., Colucci, W. S., et al. (2001). Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. *New England Journal of Medicine*, 344, 1358–1365.

Aspirin

- Cleland, J. G. (2002). Is aspirin “the weakest link” in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. *Progress in Cardiovascular Disease*, 44, 275–292.
- Cyrus, T., Sung, S., Zhao, L., Funk, C. D., Tang, S., & Pratico, D. (2002, September 3). Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. *Circulation*, 106(10), 1282–1287.
- Department of Health and Human Services Food and Drug Administration, 21 CFR Part 343 [Docket No. 77N–094A] RIN 0910–AA01. (1998, October 23). Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use: Final Rule for Professional Labeling of Aspirin, Buffered Aspirin, and Aspirin in Combination with Antacid Drug Products. Federal Register, Vol. 63, No. 205, Rules and Regulations. Available at <http://www.fda.gov/ohrms/dockets/98fr/102398c.pdf>
- FDA/Center for Drug Evaluation and Research. (n.d.). Before Using Aspirin to Lower Your Risk of Heart Attack or Stroke, Here Is What You Should Know: Only a health professional can safely decide if the regular use of aspirin to prevent a heart attack or stroke is right for you. Last updated March 13, 2003, at <http://www.fda.gov/cder/consumerinfo/AspirinFactSheet.pdf>.
- Hayden, M., Pignone, M., Phillips, C., & Mulrow, C. (2002, January 15). Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*, 136(2), 161–172. Summary for patients in *Annals of Internal Medicine*, 136(2), I55.

- Second International Study of Infarct Survival Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet*, 2, 349–360.
- U.S. Preventive Services Task Force. (2002, January 15) Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. *Annals of Internal Medicine*, 136(2), 157–160.

ACE Inhibitors

- Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. (1993). Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet*, 342, 821–828.
- Anderson, T. J., Elstein, E., Haber, H., & Charbonneau, F. (2000). Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). *Journal of the American College of Cardiology*, 35, 60–66.
- CONSENSUS Trial Study Group. (1987). Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Study. *New England Journal of Medicine*, 316, 1429–1435.
- Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998, March 5). The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *New England Journal of Medicine*, 338(10), 645–652.
- Hirsch, A. T., Talsness, C. E., Schunkert, H., Paul, M., & Dzau, V. J. (1991). Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. *Circulation Research*, 69, 475–482.
- ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. (1995). ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. *Lancet*, 345, 669–685.
- Kjoller-Hansen, L., Steffensen, R., & Grande, P. (2000, March 15). The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). *Journal of the American College of Cardiology*, 35(4), 881–888.
- Kober, L., Torp-Pedersen, C., Carlsen, J. E., et al. (1995). A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *New England Journal of Medicine*, 333, 1670–1676.
- Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *New England Journal of Medicine*, 329, 1456–1462.
- Mancini, G. B., Henry, G. C., Macaya, C., et al. (1996). Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. *Circulation*, 94, 258–265.
- Oosterga, M., Voors, A. A., Pinto, Y. M., Buikema, H., Grandjean, J. G., Kingma, J. H., Crijns, H. J., & van Gilst, W. H. (2001, March 1). Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study): QUinapril on Vascular Ace and Determinants of Ischemia. *American Journal of Cardiology*, 87(5), 542–546.

- Pfeffer, M. A., Braunwald, E., Moye, L. A., et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. *New England Journal of Medicine*, 327, 669–677.
- Pitt, B., Poole-Wilson, P. A., Segal, R., et al. (2000). Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial—the Losartan Heart Failure Survival Study ELITE II. *Lancet*, 355, 1582–1587.
- Pitt, B., Segal, R., Martinez, F. A., et al. (1997). Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet*, 349, 747–752.
- Scholken, B. A., & Landgraf, W. (2002). ACE inhibition and atherogenesis. *Canadian Journal of Physiology and Pharmacology*, 80, 354–359.
- SOLVD Investigators. (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *New England Journal of Medicine*, 325, 293–302.
- SOLVD Investigators. (1992). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *New England Journal of Medicine*, 327, 685–691.
- Tatti, P., Pahor, M., Byington, R. P., Di Mauro, P., Guarisco, R., Strollo, G., & Strollo, F. (1998, April 21). Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care*, 21(4), 597–603.
- Wright, J. T., Jr., Bakris, G., Greene, T., Agodoa, L. Y., Appel, L. J., Charleston, J., Cheek, D., Douglas-Baltimore, J. G., Gassman, J., Glassock, R., Hebert, L., Jamerson, K., Lewis, J., Phillips, R. A., Toto, R. D., Middleton, J. P., & Rostand, S. G.; African American Study of Kidney Disease and Hypertension Study Group. (2002, November 20). Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. *Journal of the American Medical Association*, 288(19), 2421–2431.
- Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., & Dagenais, G. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *New England Journal of Medicine*, 342, 145–153.

Statins

- Brown, B. G., Zhao, X. Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., Frohlich, J., & Albers, J. J. (2002, November 29). Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *New England Journal of Medicine*, 345(22), 1583–1592. Summary for patients in *Current Cardiology Reports* 4(6), 486.
- Chilton, R., & O'Rourke, R. A. (2001, December). The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease. *Current Problems in Cardiology*, 26(12), 734–764.
- Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: A randomised placebo-controlled trial. *Lancet*, 361, 2005–2016. [Source for Figure 4.1]
- Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., & Gotto, A. M., Jr. (1998, May 27).

- Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *Journal of the American Medical Association*, 279(20), 1615–1622.
- Heart Protection Study Collaborative Group. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. *Lancet*, 360, 7–22. [Source for Figure 4.1]
- Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *New England Journal of Medicine*, 339, 1349–1357. [Source for Figure 4.1]
- Pfeffer, M. A., Keech, A., Sacks, F. M., Cobbe, S. M., Tonkin, A., Byington, R. P., Davis, B. R., Friedman, C. P., & Braunwald, E. (2002, May 21). Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. *Circulation*, 105(20), 2341–2346.
- Pitt, B., Waters, D., Brown, W. V., van Boven, A. J., Schwartz, L., Title, L. M., Eisenberg, D., Shurzinske, L., & McCormick, L. S. (1999, July 8). Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *New England Journal of Medicine*, 341(2), 70–76.
- Sacks, F. M., Pfeffer, M. A., Moye, L. A., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *New England Journal of Medicine*, 335, 1001–1009. [Source for Figure 4.1]
- Scandinavian Simvastatin Survival Study Group. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet*, 344, 1383–1389. [Source for Figure 8.1]
- Schwartz, G. G., Olsson, A. G., Ezekowitz, M. D., Ganz, P., Oliver, M. F., Waters, D., Zeiher, A., Chaitman, B. R., Leslie, S., & Stern, T.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. (2001, April 4). Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled trial. *Journal of the American Medical Association*, 285(13), 1711–1718. [Source for Figure 4.1]
- Sever, P. S., Dahlof, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., Nieminen, M., O'Brien, E., & Ostergren, J.; ASCOT investigators. (2003, April 5). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. *Lancet*, 361(9364), 1149–1158.
- Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H., & Packard, C. J. (1995, November 16). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *New England Journal of Medicine*, 333(20), 1301–1307.
- Velasco, J. A. (1999). After 4S, CARE and LIPID—Is evidence-based medicine being practised? *Atherosclerosis*, 147(Supplement 1), S39–S44.

ARBs

- Brenner, B. M., Cooper, M. E., de Zeeuw, D., et al. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *New England Journal of Medicine*, 345, 861–869.
- Cohn, J. N., & Tognoni, G. (2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *New England Journal of Medicine*, 345(23), 1667–1675.
- Lewis, E. J. (2002). The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. *American Journal of Hypertension*, 10, 123S–128S.
- Lewis, E. J., Hunsicker, L. G., Clarke, W. R., et al. (2001). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *New England Journal of Medicine*, 345, 851–860.
- Pfeffer, M. A., Swedberg, K., Granger, C. B., et al. (2003). Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. *Lancet*, 362, 759–766.
- Sasso, F. C., Carbonara, O., Persico, M., et al. (2002). Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: A randomized double-blind placebo-controlled crossover study. *Diabetes Care*, 25, 1909–1913.

Diuretics

- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002, December 18). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Journal of the American Medical Association*, 288(23), 2981–2997.
- Weinberger, M. H. (1992). Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. *European Heart Journal*, 13(Supplement G), 5–9.

Calcium Blockers

- Packer, M., O'Connor, C. M., Ghali, J. K., et al. (1996). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. *New England Journal of Medicine*, 335, 1107–1114.
- Pahor, M., Psaty, B. M., Alderman, M. H., Applegate, W. B., Williamson, J. D., Cavazzini, C., & Furberg, C. D. (2000, December 9). Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. *Lancet*, 356(9246), 1949–1954.

Vitamins

- Liem, A., Reynierse-Buitenwerf, G. H., Zwinderman, A. H., Jukema, J. W., & van Veldhuisen, D. J. (2003, June 18). Secondary prevention with folic acid: effects on clinical outcomes. *Journal of the American College of Cardiology*, 41(12), 2105–2113.

- Morris, C. D., & Carson, S. (2003, July 1). Routine vitamin supplementation to prevent cardiovascular disease: A summary of the evidence for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*, 139(1), 56–70.
- Schnyder, G., Roffi, M., Pin, R., Flammer, Y., Lange, H., Eberli, F. R., Meier, B., Turi, Z. G., & Hess, O. M. (2001, November 29). Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *New England Journal of Medicine*, 345(22), 1593–1600.
- U.S. Preventive Services Task Force. (2003, July 1). Routine vitamin supplementation to prevent cancer and cardiovascular disease: Recommendations and rationale. *Annals of Internal Medicine*, 139(1), 51–55.
- U.S. Preventive Services Task Force. (2003, July 1). Summaries for patients. Taking vitamin supplements to prevent cardiovascular disease and cancer: Recommendations from the U.S. Preventive Services Task Force. *Annals of Internal Medicine*, 139(1), 1–76.
- Vivekananthan, D. P., Penn, M. S., Sapp, S. K., Hsu, A., & Topol, E. J. (2003, June 14). Use of antioxidant vitamins for the prevention of cardiovascular disease: Meta-analysis of randomised trials. *Lancet*, 361(9374), 2017–2023.
- Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., & Sleight, P. (2000). Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *New England Journal of Medicine*, 342, 154–160.

Lifestyle

- Appel, L. J., Champagne, C. M., Harsha, D. W., Cooper, L. S., Obarzanek, E., Elmer, P. J., Stevens, V. J., Vollmer, W. M., Lin, P. H., Svetkey, L. P., Stedman, S. W., & Young, D. R.; Writing Group of the PREMIER Collaborative Research Group. (2003, April 23–30). Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. *Journal of the American Medical Association*, 289(16), 2083–2093.
- Appel, L. J., Moore, T. J., Obarzanek, E., Vollmer, W. M., Svetkey, L. P., Sacks, F. M., Bray, G. A., Vogt, T. M., Cutler, J. A., Windhauser, M. M., Lin, P. H., & Karanja, N. (1997, April 17). A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *New England Journal of Medicine*, 336(16), 1117–1124.
- Ezzati, M., Hoorn, S. V., Rodgers, A., Lopez, A. D., Mathers, C. D., & Murray, C. J.; Comparative Risk Assessment Collaborating Group. (2003, July 26). Estimates of global and regional potential health gains from reducing multiple major risk factors. *Lancet*, 362(9380), 271–280.
- Ornish, D., Scherwitz, L. W., Billings, J. H., Brown, S. E., Gould, K. L., Merritt, T. A., Sparler, S., Armstrong, W. T., Ports, T. A., Kirkeeide, R. L., Hogeboom, C., & Brand, R. J. (1998, December, 16). Intensive lifestyle changes for reversal of coronary heart disease. *Journal of the American Medical Association*, 280(23), 2001–2007.
- Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., 3rd, Simons-Morton, D. G., Karanja, N., & Lin, P. H.; DASH-Sodium Collaborative Research Group. (2001, January 4). Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *New England Journal of Medicine*, 344(1), 3–10.

- Sebregts, E. H., Falger, P. R., & Bar, F. W. (2000, April-May). Risk factor modification through nonpharmacological interventions in patients with coronary heart disease. *Journal of Psychosomatic Research*, 48(4-5), 425-441.

Guidelines for Management

- Chobanian, A. V., Bakris, G. L., Black, H. R., et al. (2003). The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. *Journal of the American Medical Association*, 289, 2560-2571.
- Gordon, A. J., & Macpherson, D. S. (2003, June 1). Guideline chaos: Conflicting recommendations for preoperative cardiac assessment. *American Journal of Cardiology*, 91(11), 1299-1303.
- National Institutes of Health. (2002). Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Full Report. Vol. 2003. Available at <http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm>
- Sackner-Bernstein, J. (2003). The JNC 7 hypertension guidelines. *Journal of the American Medical Association*, 290, 1312.
- Sackner-Bernstein, J. (in press). Why are the JNC-7 targets different from the evidence? [Letter to the editor]. *Journal of the American Medical Association*.
- Wolf, S. H. (1999, December 22-29). The need for perspective in evidence-based medicine. *Journal of the American Medical Association*, 282(24), 2358-2365.

Characteristics or Conditions

Diabetes

- Adler, A. I., Stratton, I. M., Neil, H. A., et al. (2000). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. *British Medical Journal*, 321, 412-419.
- American Diabetes Association. (2003). National Diabetes Fact Sheet. Vol. 2003.
- Balkau, B., Shipley, M., Jarrett, R. J., Pyorala, K., Pyorala, M., Forhan, A., & Eschwege, E. (1998, March). High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. *Diabetes Care*, 21(3), 360-367.
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. (2002, February 10). Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. *New England Journal of Medicine*, 342(6), 381-389.
- Garvey, W. T., & Hermayer, K. L. (1998). Clinical implications of the insulin resistance syndrome. *Clinical Cornerstone*, 1, 13-28.
- Giugliano, D., Acampora, R., Marfella, R., et al. (1997). Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: A randomized, controlled trial. *Annals of Internal Medicine*, 126, 955-959.

- Haffner, S. M. (1999). Epidemiology of insulin resistance and its relation to coronary artery disease. *American Journal of Cardiology*, 84, 11J–14J.
- Khaw, K-T., Wareham, N., Luben, R., et al. (2001). Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). *British Medical Journal*, 322, 1–6. [Source for Figure 10.1]
- McGill, H. C., Jr., McMahan, C. A., Malcom, G. T., Oalmann, M. C., & Strong, J. P. (1995, April). Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 15(4), 431–440.
- Pontirolì, A. E., Pacchioni, M., Camisasca, R., & Lattanzio, R. (1998). Markers of insulin resistance are associated with cardiovascular morbidity and predict overall mortality in long-standing non-insulin-dependent diabetes mellitus. *ACTA Diabetologica*, 35, 52–56.
- Raji, A., Seely, E. W., Bekins, S. A., Williams, G. H., & Simonson, D. C. (2003). Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. *Diabetes Care*, 26, 172–178.
- Reneland, R., Alvarez, E., Andersson, P. E., Haenni, A., Byberg, L., & Lithell, H. (2000). Induction of insulin resistance by beta-blockade but not ACE-inhibition: Long-term treatment with atenolol or trandolapril. *Journal of Human Hypertension*, 14, 175–180.
- Saydah, S. H., Loria, C. M., Eberhardt, M. S., & Brancati, F. L. (2001, March). Subclinical states of glucose intolerance and risk of death in the U.S. *Diabetes Care*, 24(3), 447–453.
- Shargorodsky, M., Wainstein, G., Gavish, E., et al. (2003). Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. *American Journal of Hypertension*, 16, 617–622.
- Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., & Holman, R. R. (2000, August 12). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. *British Medical Journal*, 321(7258), 405–412.
- Torlone, E., Britta, M., Rambotti, A. M., et al. (1993). Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes. *Diabetes Care*, 16, 1347–1355.
- U.K. Prospective Diabetes Study Group. (1998, September 12). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *British Medical Journal*, 317(7160), 713–720.

Hypertension

- Adler, A. I., Stratton, I. M., Neil, H. A., Yudkin, J. S., Matthews, D. R., Cull, C. A., Wright, A. D., Turner, R. C., & Holman, R. R. (2000, August 12). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. *British Medical Journal*, 321(7258), 412–419.
- Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlof, B., Elmfeldt, D., Julius, S., Menard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998, June 13). Effects of intensive

- blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet*, 351(9118), 1755–1762.
- Kannel, W. B. (1996). Cardioprotection and antihypertensive therapy: The key importance of addressing the associated coronary risk factors (the Framingham experience). *American Journal of Cardiology*, 77, 6B–11B.
- Kannel, W. B. (2000). Elevated systolic blood pressure as a cardiovascular risk factor. *American Journal of Cardiology*, 85, 251–255.
- Lewington, S., Clarke, R., Qizilbash, N., Peto, R., & Collins, R. (2002). Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*, 360, 1903–1913. [Source for Figure 6.1]
- Muscholl, M. W., Hense, H.-W., Brockel, U., et al. (1998). Changes in left ventricular structure and function in patients with white coat hypertension: Cross sectional survey. *British Medical Journal*, 317, 565–570. [Source for Figure 7.2]
- Plante, G. E. (1994). The blood vessel as a target organ in hypertension: protective effect of perindopril. *Canadian Journal of Cardiology*, 10(Supplement D), 25D–29D.
- Pooling Project Research Group. (1978). Relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: Final Report of the Pooling Project. *Journal of Chronic Diseases*, 31, 201–306.
- Seshadri, S., Wolf, P. A., Beiser, A., et al. (2001). Elevated midlife blood pressure increases stroke risk in elderly persons: The Framingham Study. *Archives of Internal Medicine*, 161, 2343–2350.
- Vasan, R. S., Beiser, A., Seshadri, S., et al. (2002). Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. *Journal of the American Medical Association*, 287, 1003–1010. [Source for Figure 7.1]
- Vasan, R. S., Larson, M. G., Leip, E. P., et al. (2001). Impact of high-normal blood pressure on the risk of cardiovascular disease. *New England Journal of Medicine*, 345, 1291–1297.
- Wolf-Maier, K., Cooper, R. S., Banegas, J. R., Giampaoli, S., Hense, H. W., Joffres, M., Katarinen, M., Poulter, N., Primatesta, P., Rodriguez-Artalejo, F., Stegmayr, B., Thamm, M., Tuomilehto, J., Vanuzzo, D., & Vescio, F. (2003, May 14). Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. *Journal of the American Medical Association*, 289(18), 2363–2369.

Cholesterol and the Vessel Wall

- De Franco, A. C., & Nissen, S. E. (2001). Coronary intravascular ultrasound: implications for understanding the development and potential regression of atherosclerosis. *American Journal of Cardiology*, 88, 7M–20M.
- Dzau, V. J. (1993). Tissue renin-angiotensin system in myocardial hypertrophy and failure. *Archives of Internal Medicine*, 153, 937–942.
- Kannel, W. B. (1995). Range of serum cholesterol values in the population developing coronary artery disease. *American Journal of Cardiology*, 76, 69C–77C.
- Maseri, A., & Fuster, V. (2003, April 29). Is there a vulnerable plaque? *Circulation*, 107(16), 2068–2071.

- McGill, H. C., Jr., McMahan, C. A., Herderick, E. E., Zieske, A. W., Malcom, G. T., Tracy, R. E., & Strong, J. P.; Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. (2002, June 11). Obesity accelerates the progression of coronary atherosclerosis in young men. *Circulation*, *105*(23), 2712–2718.
- McGill, H. C., Jr., McMahan, C. A., Malcom, G. T., Oalmann, M. C., & Strong, J. P. (1997, January). Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *17*(1):95–106.
- McGill, H. C., Jr., McMahan, C. A., Zieske, A. W., Malcom, G. T., Tracy, R. E., & Strong, J. P. (2001, March 20). Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. *Circulation*, *103*(11), 1546–1550.
- McGill, H. C., Jr., McMahan, C. A., Zieske, A. W., Sloop, G. D., Walcott, J. V., Troxclair, D. A., Malcom, G. T., Tracy, R. E., Oalmann, M. C., & Strong, J. P. (2000, August). Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *20*(8), 1998–2004.
- McGill, H. C., Jr., McMahan, C. A., Zieske, A. W., Tracy, R. E., Malcom, G. T., Herderick, E. E., & Strong, J. P. (2000, July 25). Association of coronary heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth. *Circulation*, *102*(4), 374–379.
- Nissen, S. E. (1999). Shortcomings of coronary angiography and their implications in clinical practice. *Cleveland Clinic Journal of Medicine*, *66*, 479–485.
- Nissen, S. E. (2000). Rationale for a post-intervention continuum of care: Insights from intravascular ultrasound. *American Journal of Cardiology*, *86*, 12H–17H.
- Nissen, S. E. (2002). Who is at risk for atherosclerotic disease? Lessons from intravascular ultrasound. *American Journal of Medicine*, *112*(Supplement 8A), 27S–33S.
- Rainwater, D. L., McMahan, C. A., Malcom, G. T., Scheer, W. D., Roheim, P. S., McGill, H. C., Jr., & Strong, J. P. (1999, March). Lipid and apolipoprotein predictors of atherosclerosis in youth: Apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *19*(3), 753–761.
- Sharrett, A. R., Ballantyne, C. M., Coady, S. A., et al., for the Atherosclerosis Risk in Communities Study Group. (2001). Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*, *104*, 1108–1113. [Source for Figure 4.2]
- Tuzcu, E. M., Kapadia, S. R., Tutar, E., et al. (2001). High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound. *Circulation*, *103*, 2705–2710. [Source for Figure 2.2]
- Wilson, P. W., & Kannel, W. B. (1993). Hypercholesterolemia and coronary risk in the elderly: The Framingham Study. *American Journal of Geriatric Cardiology*, *2*, 56.

Obesity

- Kannel, W. B., Wilson, P. W., Nam, B. H., & D'Agostino, R. B. (2002). Risk stratification of obesity as a coronary risk factor. *American Journal of Cardiology*, *90*, 697–701.

- Kenchaiah, S., Evans, J. C., Levy, D., et al. (2002). Obesity and the risk of heart failure. *New England Journal of Medicine*, *347*, 305–313.
- Lee, M., Manson, J. E., Hennekens, C. H., & Paffenbarger, R. S. (1993). Body weight and mortality: A 27-year follow-up of middle-aged men. *Journal of the American Medical Association*, *270*, 2823–2828.
- Lew, E. A., & Garfinkel, L. (1979). Variations in mortality by weight among 750,000 men and women. *Journal of Chronic Diseases*, *32*, 563–576. [Source for Figure 11.1]
- McGill, H. C., Jr., McMahan, C. A., Herderick, E. E., Zieske, A. W., Malcom, G. T., Tracy, R. E., & Strong, J. P.; Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. (2002, June 11). Obesity accelerates the progression of coronary atherosclerosis in young men. *Circulation*, *105*(23), 2712–2718.
- Willett, W. C., Manson, J. E., Stampfer, M. J., et al. (1995). Weight, weight change, and coronary heart disease in women: Risk within the normal weight range. *Journal of the American Medical Association*, *273*, 461–465.

Women

- Burke, A. P., Farb, A., Malcom, G. T., Liang, Y., Smialek, J., & Virmani, R. ((1998, June 2). Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. *Circulation*, *97*(21), 2110–2116.
- Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., & Vittinghoff, E. (1998, August 19). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *Journal of the American Medical Association*, *280*(7), 605–613.
- Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., Strickland, O. L., Wong, N. D., Crouse, J. R., Stein, E., & Cushman, M.; Women's Health Initiative Investigators. (2003, August 7). Estrogen plus progestin and the risk of coronary heart disease. *New England Journal of Medicine* *349*(6), 523–534.
- Marcuccio, E., Loving, N., Bennett, S. K., & Hayes, S. N. (2003, January-February). A survey of attitudes and experiences of women with heart disease. *Womens Health Issues*, *13*(1), 23–31.
- Rapp, S. R., Espeland, M. A., Shumaker, S. A., Henderson, V. W., Brunner, R. L., Manson, J. E., Gass, M. L., Stefanick, M. L., Lane, D. S., Hays, J., Johnson, K. C., Coker, L. H., Dailey, M., & Bowen, D.; WHIMS Investigators. (2003, May 28). Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. *Journal of the American Medical Association*, *289*(20), 2663–2672.
- Shumaker, S. A., Legault, C., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones, B. N., 3rd, Assaf, A. R., Jackson, R. D., Kotchen, J. M., Wassertheil-Smoller, S., & Wactawski-Wende, J.; WHIMS Investigators. (2003, May 28). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. *Journal of the American Medical Association*, *289*(20), 2651–2662.
- Stampfer, M. J., Hu, F. B., Manson, J. E., Rimm, E. B., & Willett, W. C. (2000, July 6). Primary prevention of coronary heart disease in women through diet and lifestyle. *New England Journal of Medicine*, *343*(1), 16–22.

Wassertheil-Smoller, S., Hendrix, S. L., Limacher, M., Heiss, G., Kooperberg, C., Baird, A., Kotchen, T., Curb, J. D., Black, H., Rossouw, J. E., Aragaki, A., Safford, M., Stein, E., Laowattana, S., & Mysiw, W. J.; WHI Investigators. (2003, May 28). Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. *Journal of the American Medical Association*, 289(20), 2673-2684.

HIV

- Bozzette, S. A., Ake, C. F., Tam, H. K., Change, S. W., & Louis, T. A. (2002). Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. *New England Journal of Medicine*, 348, 702-710.
- Currier, J. S., Taylor, A., Boyd, F., Dezii, C. M., Kawabata, H., Burtcel, B., Maa, J. F., Hodder, S. (2003, August 1). Coronary heart disease in HIV-infected individuals. *Journal of Acquired Immune Deficiency Syndrome*, 33(4), 506-512.
- David, M. H., Hornung, R., & Fichtenbaum, C. J. (2002, January 1). Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. *Clinical Infectious Diseases*, 34(1), 98-102.
- Grunfeld C., Kotler D.P., Hamadeh, R., Tierney, A., Wang J., Pierson, RN. (1989). Hypertriglyceridemia in the acquired immunodeficiency syndrome. *American Journal of Medicine*, 86, 27-31.
- Lenert, L. A., Feddersen, M., Sturley, A., & Lee, D. (2002). Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. *American Journal of Medicine*, 113, 229-232.
- Rebolledo, M. A., Krogstad, P., Chen, F., Shannon, K. M., & Klitzner, T. S. (1998). Infection of human fetal cardiac myocytes by a human immunodeficiency virus-1-derived vector. *Circulation Research*, 83, 738-742.

Sudden Death

- Burke, A. P., Kolodgie, F. D., Farb, A., Weber, D. K., Malcom, G. T., Smialek, J., & Virmani, R. (2001, February 20). Healed plaque ruptures and sudden coronary death: Evidence that subclinical rupture has a role in plaque progression. *Circulation*, 103(7), 934-940.
- Farb, A., Burke, A. P., Tang, A. L., Liang, T. Y., Mannan, P., Smialek, J., & Virmani, R. (1996, April 1). Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death. *Circulation*, 93(7), 1354-1363.
- Farb, A., Tang, A. L., Burke, A. P., Sessums, L., Liang, Y., & Virmani, R. (1995, October 1). Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. *Circulation*, 92(7), 1701-1709.
- Kannel, W. B., Wilson, P. W., D'Agostino, R. B., & Cobb, J. (1998). Sudden coronary death in women. *American Heart Journal*, 136, 205-212.
- Moss, A. J., Zareba, W., Hall, W. J., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *New England Journal of Medicine*, 346, 877-883.

About the Author

Dr. Jonathan Sackner Bernstein is Director of Clinical Research at the Heart Failure Prevention and Treatment Clinic at the Heart Failure and Cardiomyopathy Center at North Shore University Hospital in Manhasset, New York. He has been published in *Circulation*, *Transplantation* and the *Journal of the American Medical Association*. He majored in electrical engineering at the University of Pennsylvania and graduated from Jefferson Medical College before completing his medicine and cardiology training at Mount Sinai Hospital in New York City. Prior to starting the Prevention and Treatment Clinic at North Shore, he was on the full-time faculty of Columbia University's medical school in New York.

Over the last year, Dr. Bernstein has presented research at the annual meetings of the American Heart Association, the American College of Cardiology and the Heart Failure Society of America and at programs sponsored by hospitals such as Johns Hopkins, the Winters Center for Heart Failure Research at the Texas Heart Institute and Albany Medical College. He has lectured at the European Heart House, the InterAmerican College of Cardiology, the Canadian Cardiovascular Society, the International Society for Heart Research and the German Society for Prevention and Rehabilitation of Cardiovascular Disease.

He participated in the creation of treatment guidelines for Action-HF and the Heart Failure Society of America for the treatment of heart failure. Dr. Bernstein is currently a member of the Clinical Cardiology Council of the American Heart Association, the Heart Failure Society of America and is a Fellow of the American College of Cardiology.

Much of his research focuses on patients with heart failure, an advanced form of heart disease. He also has helped run international trials of heart attack treatments. His current research focuses on the treatment of fatigue in people with heart disease.

